Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.
Reinhard Dummer(University of Zurich), Axel Hauschild(Kiel University), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Lisa Licitra(University of Milan), Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Inserm), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob, B. Guillot(Université de Montpellier), Nicolás Meyer(Université Toulouse III - Paul Sabatier), D. Scott Ernst, Laurent Mortier, Rainer Kunstfeld(Vienna General Hospital), Sarah Williams(Ruhrlandklinik), Johan Hansson(Karolinska University Hospital), Brigitte Dréno(Inserm), Ioannis Xynos(Roche (United Kingdom)), A. Fittipaldo(Roche (United Kingdom))
Cited by 22
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k